Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

Summary

The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.

Timeline

Start

2014-06-09

Primary completion

2017-03-30

Completion

2018-01-19

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient enrollment, no safety or efficacy concerns”

Drugs

Indications